The Ledger

A radiopharmaceutical drug rejected by the Food and Drug Administration six weeks ago just became the trigger for one of the biggest deals nuclear medicine has ever seen. Telix Pharmaceuticals announced September 20, 2026 a definitive agreement to acquire ITM Isotope Technologies Munich SE, the German isotope supplier whose lead cancer drug ITM-11 (177Lu-edotreotide) received a Food and Drug Administration complete response letter on August 7, 2026 over manufacturing and third-party facility issues, not the underlying clinical data. Telix is paying approximately 1.65 billion dollars on a cash-free, debt-free basis, split between 1.25 billion dollars in newly issued Telix shares (105.8 million shares) and roughly 302 million dollars in assumed net debt, plus up to 700 million dollars more in milestone payments tied to future ITM-11 approvals and sales targets; the combined company projects more than 1.3 billion dollars in 2026 revenue, with Telix shareholders holding about 76.3 percent and ITM shareholders about 23.7 percent once the deal closes, expected by the end of fiscal year 2026 pending Telix shareholder approval at a meeting expected in November. Telix shares fell as much as 12 percent on the announcement as investors weighed dilution from the new share issuance against the strategic logic of locking in ITM’s manufacturing network, which includes 15-year exclusive access to Bruce Power’s Canadian reactors for isotope production. Confidence: High. This run reviewed Telix’s and ITM’s own announcements and Telix’s SEC filing directly. Sources: Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse, GlobeNewswire, Telix Pharmaceuticals Ltd, Form 6-K, SEC EDGAR, ITM Receives Complete Response Letter for 177Lu-edotreotide (ITM-11), GlobeNewswire.

HCA Healthcare just became the owner of an 8,000-student healthcare training school, the latest sign that hospital operators would rather build their own workforce pipeline than keep competing for scarce staff. HCA Healthcare completed its acquisition of The College of Health Care Professions (CHCP) on September 15, 2026, a deal it first agreed to on May 27, 2026; CHCP serves more than 8,000 students annually across 10 Texas campuses and online programs, offering more than 20 accredited healthcare career programs and, since its 1988 founding, has prepared more than 52,000 students for healthcare careers. Financial terms were not disclosed, and CHCP will keep operating under its current chief executive, Eric Bing; the deal builds on HCA’s existing education footprint, which includes Galen College of Nursing, Research College of Nursing, Mercy School of Nursing and more than 365 graduate medical education programs across 87 hospitals, making HCA one of the largest sponsors of clinical training in the country as well as the largest for-profit hospital operator. Confidence: High on the deal’s completion and CHCP’s own figures, drawn from HCA’s own announcement; Medium on the strategic framing, since HCA did not disclose enrollment-to-hire conversion data tying the acquisition directly to its own staffing needs. Sources: HCA Healthcare Completes Acquisition of the College of Health Care Professions, HCA Healthcare.

Ascension just posted its first full year of positive net income since its turnaround began, numbers that land the same week Kaufman Hall found the broader hospital sector’s margins near a 2026 low. Ascension, one of the nation’s largest nonprofit health systems, reported September 16, 2026 that its fiscal year 2026 (ended June 30) net income reached 1.5 billion dollars, with same-facility net income up 826 million dollars, or 141 percent, year over year; its operating loss narrowed to 120 million dollars from 491 million dollars a year earlier, a 371 million dollar improvement, while recurring operating earnings before interest, taxes, depreciation and amortization turned positive at 1.2 billion dollars, a 5 percent margin. Chief Executive Officer Eduardo Conrado credited “significant progress” on financial performance and access, while Chief Financial Officer Saurabh Tripathi pointed to a 696 million dollar same-facility operating-income improvement driven partly by cutting average acute-care length of stay 6.8 percent; the system also reported providing approximately 2.6 billion dollars in community benefit on a same-facility basis. Confidence: High. This run reviewed Ascension’s own financial results release directly. Sources: Ascension Releases Q4 FY26 Financial Results, Ascension.

Advocate Health, the third-largest nonprofit health system in the country, just told more than 11,500 patients and families that debt tied to their homes is gone, some of it more than 20 years old. Advocate Health announced September 20, 2026 that it is canceling all outstanding real estate liens filed against patients before it adopted a no-lien collections policy in 2022, proactively contacting affected patients and families starting with the oldest cases; the system said the process requires coordinating with its attorneys and courts in each jurisdiction where a lien was filed and will take time to fully complete. Advocate has not filed lawsuits or sought new liens or judgments since 2022, has stopped reporting delinquent medical debt to credit bureaus, and has expanded automatic financial assistance eligibility to 300 percent of the federal poverty level; the move puts a dollar figure and a headcount behind a broader industry retreat from aggressive medical-debt collection that has drawn scrutiny from state regulators and the Consumer Financial Protection Bureau. Confidence: High on Advocate’s own disclosed policy and process; Medium on the precise lien count and dollar exposure, which trade press attributes to the announcement without an independent tally reviewed this run. Sources: Commitment to affordable and accessible care, Advocate Health, Advocate Health cancels real estate liens from medical debt, Becker’s Hospital Review.

UPDATE: the bankruptcy judge overseeing Omnicare’s wind-down confirmed the plan this newsletter has tracked since it was 11 days out, closing the book on one of the largest pharmacy fraud judgments in recent memory. Judge Stacey G.C. Jernigan of the US Bankruptcy Court for the Northern District of Texas confirmed Omnicare’s Chapter 11 plan on September 17, 2026, noting it received “overwhelming acceptance” from general unsecured creditors; the CVS Health-owned long-term care pharmacy unit had already sold its operating business to GenieRx Holdings, a joint venture of Milrose Capital and Integro Asset Management, for 250 million dollars, and separately resolved a 948.8 million dollar False Claims Act judgment with a settlement in which CVS pays 130 million dollars upfront and the Department of Justice collects at least 310 million dollars more from the bankruptcy estate. The confirmed plan pays all creditors in full and is expected to take effect in October 2026, ending a case built on more than 3.3 million fraudulent prescription claims Omnicare submitted between 2010 and 2018. Confidence: High. This run reviewed trade press reporting of the court’s ruling drawn directly from the hearing. Sources: CVS Unit Omnicare Bankruptcy Plan Approved After Sale, DOJ Deal, Bloomberg Law, U.S. Bankruptcy Court for the Northern District of Texas, hearing docket, September 17, 2026.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
ITM Isotope Technologies Munich SE	Telix Pharmaceuticals	Radiopharmaceuticals, nuclear medicine supply chain	Approximately $1.65 billion upfront (cash-free, debt-free) plus up to $700 million in milestone payments; announced September 20, 2026, expected close by end of FY2026	GlobeNewswire
Two medical office buildings, Addison and Denton, Texas	Lincoln Property Company and PGIM Real Estate	Medical office buildings, outpatient real estate	Undisclosed; 103,000 square feet combined; announced September 15, 2026	Commercial Property Executive
The College of Health Care Professions	HCA Healthcare	Healthcare workforce education	Undisclosed; agreed May 27, 2026, closed September 15, 2026	HCA Healthcare

This run’s scan of FTC and DOJ merger actions and state transaction-review dockets found no new healthcare antitrust complaints or consent decrees in the last 24 to 48 hours; the MultiPlan/Claritev out-of-network repricing multidistrict litigation (MDL 3121) remains in discovery with no new development since this newsletter’s September 17 coverage. Definitive Healthcare’s special committee continues evaluating Advent International’s September 1 non-binding, $1.02-per-share going-private proposal with no public update this run; worth a full story once a formal recommendation or revised offer lands. A frontier check on the food-is-medicine and social-determinants-of-health industry, a branch this newsletter has not yet covered, found real policy and funding momentum, a fourfold increase in federal food-is-medicine funding since fiscal year 2024 and 16 states with active or pending Medicaid nutrition waivers, but no single dated transaction inside this run’s 24 to 48 hour window; worth rechecking once a specific vendor discloses a contract or funding round.